Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Axial spondyloarthritis; Sacroiliitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 22 Sep 2023 Results analyzing efficacy and safety of ixekizumab for treating Chinese patients with active r-axSpA, published in the BioDrugs
    • 03 Jun 2023 Results assessing the onset time of ixekizumab in Chinese patients with r-axSpA presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Dec 2022 Primary endpoint Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response) has been met as per the results presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top